GLP‑1 medicines have moved from metabolic workhorses to front-page news. Originally designed for diabetes, they now sit at the centre of conversations about obesity, cardiovascular risk – and increasingly, brain and cancer biology. Beneath the headlines, two distinct questions are emerging for R&D and portfolio leaders: In neurodegeneration, are GLP‑1s genuinely touching disease mechanisms in Alzheimer’s and Parkinson’s, or are they mainly cleaning up upstream metabolic and

From Single Targets to Systems Biology: A New Framework for Neurodegenerative R&D For three decades, neurodegeneration programmes have been built around a tightly focused premise: find the toxic protein, clear it from the brain, protect the vulnerable neuron. Alzheimer’s was framed as an amyloid and tau problem. Parkinson’s as a dopamine and alpha-synuclein problem. ALS as a motor neuron problem. That framing has driven real progress – from disease-modifying antibodies to g

GLP‑1 weight‑loss drugs started as diabetes medicines. Now they’re quietly becoming one of the most powerful tools in obesity treatment — and they’re still evolving. The science is advancing quickly. The harder question is whether access, cost, and policy will keep up.